Observational studyAIDS patient care and STDs2017
Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.
Observational study in AIDS patient care and STDs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Chronic kidney disease among people living with HIV on TDF based regimen: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Incidence of impaired kidney function among people with HIV: a systematic review and meta-analysis.BMC nephrology · 2022Pooled it
- Determinants of Risk Factors for Renal Impairment among HIV-Infected Patients Treated with Tenofovir Disoproxil Fumarate-Based Antiretroviral Regimen in Southern Vietnam.BioMed research international · 2020Trial
- Decline in estimated glomerular filtration rate following substitution of Nevirapine-based regimen with Tenofovir-based regimen in Indonesia.BMC infectious diseases · 2025Observational
- Quality-of-life changes six months after the programmatic switch from nevirapine to dolutegravir-based ART in stable PLWH: a prospective cohort study in Indonesia.Scientific reports · 2025Article
- Article
- Long-Term Evolution of Renal Function Among People with HIV who Received Tenofovir Alafenamide-Containing Antiretroviral Therapy.Infectious diseases and therapy · 2025Article
- Article
- Association between tenofovir plasma trough concentrations in the early stage of administration and discontinuation of up to five years tenofovir disoproxil fumarate due to renal function-related adverse events in Japanese HIV-1 infected patients.Journal of pharmaceutical health care and sciences · 2024Article
- Prevalence and Risk Factors for Renal Insufficiency among Adults Living with HIV in Tanzania: Results from a Cross-Sectional Study in 2020-2021.Healthcare (Basel, Switzerland) · 2024Article
- Prevalence and risk factors for kidney disease among hospitalized PLWH in China.AIDS research and therapy · 2023Article
- Effect of tenofovir containing ART on renal function in patients with moderate/severe reduced creatinine clearance at baseline: A retrospective study at two referral hospitals in Namibia.Pharmacology research & perspectives · 2023Article
- Factors Associated with Antiretroviral Therapy Toxicity Out-Comes in Patients with and without Hypertension.International journal of environmental research and public health · 2022Article
- The Incidence and Risk Factors of Renal Insufficiency among Korean HIV infected Patients: The Korea HIV/AIDS Cohort Study.Infection & chemotherapy · 2022Article
- Chronic Kidney Disease in a Large National Human Immunodeficiency Virus Treatment Program.Healthcare (Basel, Switzerland) · 2022Article
- Comparison of Renal Function Biomarkers of Serum Creatinine and Cystatin C in HIV-Infected People on Dolutegravir-Containing Therapy.Infection and drug resistance · 2022Article
- Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.AIDS research and therapy · 2021Observational
- Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.Antimicrobial agents and chemotherapy · 2021Article
- Observational
- Pharmacotherapeutic options for kidney disease in HIV positive patients.Expert opinion on pharmacotherapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Little evidence is available for the incidence of chronic kidney disease (CKD) and rate of estimated glomerular filtration rate (eGFR) decrement among Asians with low body weight who are susceptible to tenofovir disoproxil fumarate (TDF) nephrotoxicity. In this 12-year observational cohort in Tokyo, we examined 1383 treatment-naïve HIV-1-infected Asians [720 started TDF-containing (TDF group) and 663 started non-TDF-containing (control) combination antiretroviral therapy (cART)]. The CKD incidence was calculated, and the effect of TDF use on CKD development was estimated using logistic regression. The eGFR slopes, before and after cART initiation, were estimated using mixed-effects linear spline models. Most patients were males (median weight, 62.6 kg; 83% started ritonavir-boosted protease inhibitors; median observation duration, 5.08 years). CKD developed in 150 patients (10.8%), with an incidence of 20.6 per 1000 person-years [confidence interval (95% CI), 17.6-24.2]. None developed end-stage renal disease. TDF use was associated with CKD [odds ratio (OR), 1.8; 95% CI, 1.00-3.13; p = 0.052]. The cumulative mean loss in the TDF group, relative to the control, increased over time after 1, 4, and 8 years of TDF exposure (-3.8, -5.5, and -9.0 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.